GLP‑1 meal & exercise guide
- A GLP‑1 Weekly Meal & Exercise Guide published April 20 offers a practical weekly playbook for people on GLP‑1 therapy. (glp1weeklymealandexerciseguide.substack.com) - The guide explicitly addresses people using Ozempic, Wegovy, and Mounjaro and pairs meals with exercise suggestions. (glp1weeklymealandexerciseguide.substack.com) - The author frames medication as part of a structured program combining meal planning and exercise, not as a stand‑alone solution. (glp1weeklymealandexerciseguide.substack.com)
A Substack newsletter published April 20 is turning GLP-1 treatment into a weekly routine of meals and workouts, not just a prescription. (glp1weeklymealandexerciseguide.substack.com) The post is part of “The GLP-1 Weekly Meal & Exercise Guide,” written by Dr. Onyx MD PhD, and it describes itself as a playbook for people using Ozempic, Wegovy, Mounjaro “& Beyond.” The newsletter archive shows dated weekly editions through March and April 2026. (glp1weeklymealandexerciseguide.substack.com) The April 20 edition explicitly names Ozempic, Wegovy, and Mounjaro and pairs food planning with exercise suggestions across a seven-day schedule. The publication’s home page says it is aimed at helping readers “thrive” on those drugs rather than simply take them. (glp1weeklymealandexerciseguide.substack.com) GLP-1 drugs reduce appetite and slow stomach emptying, which means many patients eat less without necessarily eating better. That has created a market for guides that focus on protein, hydration, fiber, and smaller meals that are easier to tolerate. (foodzilla.com) The drug labels themselves already frame treatment as more than medication alone. Ozempic is approved for adults with type 2 diabetes, Wegovy is approved for chronic weight management with diet and increased physical activity, and Mounjaro is approved as an adjunct to diet and exercise for type 2 diabetes. (accessdata.fda.gov 1) (accessdata.fda.gov 2) (accessdata.fda.gov 3) Interest in that kind of support has grown with use of the drugs. A KFF poll published in May 2024 found 12% of U.S. adults said they had taken a GLP-1 drug, and a Centers for Disease Control and Prevention data brief found 26.5% of adults with diagnosed diabetes used GLP-1 injectables in 2024. (kff.org) (cdc.gov) The exercise piece addresses a problem doctors and researchers have been tracking in trials: weight loss can include lean mass, not just fat. In a semaglutide body-composition substudy, total lean body mass fell 9.7% over 68 weeks, while a tirzepatide SURMOUNT-1 substudy also found losses in lean mass alongside larger drops in fat mass. (academic.oup.com) (pmc.ncbi.nlm.nih.gov) That helps explain why GLP-1 coaching is increasingly packaged around structure: what to eat when appetite is low, how to space protein through the day, and when to add walking or strength work. The April 20 guide fits that model by treating the medication as one part of a weekly regimen. (glp1weeklymealandexerciseguide.substack.com) (clinicaltrials.gov) The thread running through the guide is simple: the injection is weekly, but the work around it is daily. That is the pitch behind a growing layer of GLP-1 media, apps, and meal plans now building around the drugs. (glp1weeklymealandexerciseguide.substack.com 1) (glp1weeklymealandexerciseguide.substack.com 2)